Gene expression profiling in non-small cell lung cancer

from molecular mechanisms to clinical application

Russell D Petty, Marianne C Nicolson, Keith M Kerr, Elaina Collie-Duguid, Graeme I Murray

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.

Original languageEnglish
Pages (from-to)3237-3248
Number of pages12
JournalClinical Cancer Research
Volume10
Issue number10
DOIs
Publication statusPublished - 15 May 2004

Keywords

  • Carcinoma, Non-Small-Cell Lung
  • Cell Line, Tumor
  • DNA, Complementary
  • Disease Progression
  • Gene Expression Profiling
  • Humans
  • Lung Neoplasms
  • Oligonucleotide Array Sequence Analysis
  • Phenotype
  • Prognosis
  • Proteome
  • RNA
  • RNA, Messenger
  • Tumor Markers, Biological
  • Messenger-RNA Expression
  • CDNA Microarray
  • Anticancer Drugs
  • Altered Expression
  • Serial Analysis
  • Adenocarcinoma
  • Chemotherapy
  • Sensitivity
  • Prediction
  • Carcinomas

Cite this

Gene expression profiling in non-small cell lung cancer : from molecular mechanisms to clinical application. / Petty, Russell D; Nicolson, Marianne C; Kerr, Keith M; Collie-Duguid, Elaina; Murray, Graeme I.

In: Clinical Cancer Research, Vol. 10, No. 10, 15.05.2004, p. 3237-3248.

Research output: Contribution to journalArticle

@article{b3d8658ea3e24d0fb9d3cbdada53e3cb,
title = "Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application",
abstract = "Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.",
keywords = "Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, DNA, Complementary, Disease Progression, Gene Expression Profiling, Humans, Lung Neoplasms, Oligonucleotide Array Sequence Analysis, Phenotype, Prognosis, Proteome, RNA, RNA, Messenger, Tumor Markers, Biological, Messenger-RNA Expression, CDNA Microarray, Anticancer Drugs, Altered Expression, Serial Analysis, Adenocarcinoma, Chemotherapy, Sensitivity, Prediction , Carcinomas",
author = "Petty, {Russell D} and Nicolson, {Marianne C} and Kerr, {Keith M} and Elaina Collie-Duguid and Murray, {Graeme I}",
year = "2004",
month = "5",
day = "15",
doi = "10.1158/1078-0432.CCR-03-0503",
language = "English",
volume = "10",
pages = "3237--3248",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Gene expression profiling in non-small cell lung cancer

T2 - from molecular mechanisms to clinical application

AU - Petty, Russell D

AU - Nicolson, Marianne C

AU - Kerr, Keith M

AU - Collie-Duguid, Elaina

AU - Murray, Graeme I

PY - 2004/5/15

Y1 - 2004/5/15

N2 - Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.

AB - Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.

KW - Carcinoma, Non-Small-Cell Lung

KW - Cell Line, Tumor

KW - DNA, Complementary

KW - Disease Progression

KW - Gene Expression Profiling

KW - Humans

KW - Lung Neoplasms

KW - Oligonucleotide Array Sequence Analysis

KW - Phenotype

KW - Prognosis

KW - Proteome

KW - RNA

KW - RNA, Messenger

KW - Tumor Markers, Biological

KW - Messenger-RNA Expression

KW - CDNA Microarray

KW - Anticancer Drugs

KW - Altered Expression

KW - Serial Analysis

KW - Adenocarcinoma

KW - Chemotherapy

KW - Sensitivity

KW - Prediction

KW - Carcinomas

U2 - 10.1158/1078-0432.CCR-03-0503

DO - 10.1158/1078-0432.CCR-03-0503

M3 - Article

VL - 10

SP - 3237

EP - 3248

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -